SAM #36C24826Q0987

Sole Source Synthesis of NPC86 Cyclic Peptide for VA Medical Center

This opportunity is a sole source procurement for the synthesis of a specialized cyclic peptide drug candidate, NPC86, for the James A. Haley VA Medical Center. - Agency: Department of Veterans Affairs, Network Contracting Office 8 (NCO 8), James A. Haley VA Medical Center - Vendor/OEM: Curia Global Inc. is specified as the sole source provider - Product: NPC86 cyclic peptide (non-GMP), 2 grams - Synthesis method: Solid Phase Peptide Synthesis (SPPS) initiated on Rink amide resin - Purity requirement: 95% by HPLC (area%, non-validated) - NAICS code: 541715 (Research and Development in the Physical, Engineering, and Life Sciences) - Period of performance: August 17, 2026, to August 16, 2027 (one year) - Commercial opportunity: Highly specialized chemistry; interested parties must provide manufacturer authorization to work with Curia Global Inc. - No competing vendors or part numbers are specified; sole source justification is based on unique expertise and capability - Potential competitors could include other peptide synthesis OEMs, but none are named in the notice - Estimated contract value is likely in the low to mid five-figure range, based on typical custom peptide synthesis pricing

Product Line Items: - NPC86 Cyclic Peptide (Non-GMP), 2 grams, synthesized to 95% purity by HPLC

Requirements: - Synthesis must use SPPS on Rink amide resin - Final product must meet purity specification - Manufacturer authorization required for any interested parties

Description

Special Notice

Special Notice

Page 4 of 4

Non-GMP Synthesis of NP-C86 (Cyclic Peptide)

James A. Haley VA Medical Center, 13000 Bruce B. Downs Blvd., Tampa, Florida 33612, intends to solicit sole source to Curia Global Inc., for the NPC86 which is a new drug designed to alleviate metabolic diseases such as T2D and neurodegenerative diseases. The chemistry to synthesize the drug is highly specialized and uses the solid state synthesis method. The target is to synthesize 2 grams of NPC86 which is acyclic peptide.

Curia will use Solid Phase Peptide Synthesis (SPPS) for this peptide, initiating the synthesis on Rink amide resin. This approach will yield an amide functionality at the C-terminal upon cleavage. The target specification for the final compound is 95% purity by HPLC (area%, non-validated).

Period of performance is 8/17/2026 to 8/16/2027. The North American Industry Classification System (NAICS) code is 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).

Any information regarding this requirement must be received no later than 7/28/2026 @ 10:00 AM EST. Please provide a letter from the manufacturer stating authorization to work with Curia Global Inc.

DISCLAIMER This request for information is issued solely for information and planning purposes only and does not constitute a solicitation. All information received in response to this request for information that is marked as proprietary will be handled accordingly. In accordance with FAR 15.201(e), responses to this notice are not offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI.

View original listing